Related by context. All words. (Click for frequent words.) 70 mifamurtide 70 EFAPROXYN 69 Junovan 68 pralatrexate 67 oral ridaforolimus 66 MOZOBIL 66 alvimopan 66 glufosfamide 65 BLA submission 65 CoFactor 65 RIGScan CR 65 ponatinib 65 talactoferrin 65 TORISEL 65 OPAXIO 65 Clolar 64 non metastatic osteosarcoma 64 MyVax R 64 PROVENGE sipuleucel T 64 Genasense 64 amrubicin 64 Orathecin 63 HGS ETR2 63 axitinib 63 interferon gamma 1b 63 Complete Response 63 FOLOTYN 63 ELACYT 63 Dacogen injection 63 custirsen 63 HGS ETR1 63 Tavocept 63 Azedra 63 RSR# 62 sapacitabine 62 IMA# 62 oxymorphone ER 62 MAA submission 62 sipuleucel T 62 Marqibo 62 Allovectin 7 ® 62 TELCYTA 62 Marketing Authorization Application 62 picoplatin 62 Biologics License Application BLA 62 TREANDA 62 Fludara 62 PROVENGE 62 GATTEX 62 temsirolimus 62 SILENOR TM 62 PXD# 62 ruxolitinib 62 vandetanib 62 Zerenex 62 TRISENOX 62 adecatumumab 62 metastatic castration resistant 62 Omigard 62 HER2 positive metastatic breast 62 Amigal 62 EndoTAG TM -1 62 Pixuvri 62 FavId 61 prGCD 61 ofatumumab 61 Onrigin TM 61 Phenoptin 61 PLK1 SNALP 61 lintuzumab 61 registrational 61 Targretin 61 Soliris TM eculizumab 61 refractory chronic lymphocytic 61 INCB# [001] 61 refractory APL 61 mCRC patients 61 LymphoStat B 61 CINTREDEKIN BESUDOTOX 61 ENRICH trial 61 refractory Hodgkin lymphoma 61 Amrubicin 61 elotuzumab 61 orBec R 61 Onrigin 61 Bronchitol 61 YONDELIS 61 BLA filing 61 mapatumumab 61 Tarceva TM 61 Taxotere ® 61 IRESSA 61 gemcitabine chemotherapy 61 Jevtana 61 VIDAZA 61 pazopanib 61 MAGE A3 ASCI 61 perifosine 61 Cloretazine R VNP#M 61 Phase 1b 61 CIMZIA TM 60 PROVENGE ® 60 Genasense ® 60 Bezielle 60 Ceplene 60 Allovectin 7 R 60 TNFerade 60 Intermezzo ® NDA 60 dose cohort 60 relapsed SCLC 60 ASA# 60 refractory PTCL 60 MEPACT 60 metastatic renal cell 60 Velcade bortezomib 60 Combidex 60 Oncophage 60 hoFH 60 Cinryze TM 60 ixabepilone 60 Augment Injectable 60 AZILECT R 60 eribulin mesylate 60 FOLOTYN ® 60 FOLFOX 60 OMAPRO 60 Torisel 60 CR# vcMMAE 60 palifosfamide 60 tamibarotene 60 Neurodex 60 Ceflatonin 60 sBLA 60 ADVEXIN 60 Phase #/#a trial 60 #D#C# 60 Panzem R NCD 60 systemic immunosuppressive drugs 60 cintredekin besudotox 60 ONTAK 60 plus dexamethasone 60 panitumumab 60 FDA Approvable Letter 60 brentuximab vedotin 60 relapsed refractory multiple myeloma 60 sorafenib tablets 60 orBec 60 APF# 60 Fibrillex TM 60 Genasense ® oblimersen 60 Biologics License Application 60 TOCOSOL Paclitaxel 60 ongoing Phase 1b 60 mRCC 60 Cloretazine ® 59 eltrombopag 59 Vectibix 59 blinatumomab 59 TYKERB 59 GAMMAGARD 59 SinuNase TM 59 BiovaxID 59 aflibercept 59 tocilizumab 59 REPLAGAL 59 Gliadel Wafer 59 azacitidine 59 Virulizin R 59 BENLYSTA 59 Complete Response letter 59 ONGLYZA ™ 59 IL# PE#QQR 59 decitabine 59 PREOS 59 Evoltra 59 clofarabine 59 vinorelbine 59 NEUMUNE 59 tafamidis 59 Clolar ® 59 ANYARA 59 Civacir 59 maribavir 59 tanespimycin 59 omega interferon 59 Nplate 59 infusional 5-FU/LV 59 Cladribine Tablets 59 BRIM2 59 trastuzumab DM1 T DM1 59 abiraterone acetate 59 alvespimycin 59 bafetinib 59 iclaprim 59 Allovectin 7 59 Dyloject TM 59 pirfenidone 59 ganetespib 59 registrational trial 59 Restanza 59 pemetrexed 59 adult chronic ITP 59 phase IIb clinical 59 refractory acute myeloid 59 Tamibarotene 59 IIa trial 59 Insegia 59 LE DT 59 Panzem R 59 Traficet EN 59 Dacogen 59 indiplon capsules 59 EGFR expressing mCRC 59 monotherapy 59 Genasense R oblimersen 59 Vidaza 59 nonclinical studies 59 FROVA 59 ZADAXIN 59 Vicinium TM 59 enzastaurin 59 OncoVEX GM CSF 59 CORLUX 59 BCR ABL inhibitor 59 T Pred 59 sargramostim 59 SPARLON 59 Rhucin ® 59 Voraxaze ™ 59 denufosol 59 Icatibant 59 TYGACIL 59 Anturol 59 Vandetanib 59 R sipuleucel T 59 metastatic RCC 59 lymphoma CTCL 59 GLP toxicology studies 59 anidulafungin 59 confirmatory Phase III 58 IMPACT IMmunotherapy 58 HRPC 58 EOquin 58 tivozanib 58 TELINTRA 58 Avastin bevacizumab 58 Aurexis 58 initiate Phase 1b 58 Stedivaze 58 trabectedin 58 torezolid phosphate 58 liprotamase 58 ZYBRESTAT 58 metastatic castrate resistant 58 lucinactant 58 standard chemotherapy regimen 58 PROMACTA 58 SNT MC# 58 ZOLINZA 58 TYZEKA 58 docetaxel chemotherapy 58 OvaRex ® MAb 58 low dose cytarabine 58 L BLP# 58 valopicitabine 58 metastatic hormone refractory 58 cutaneous T cell 58 metastatic sarcomas 58 ezogabine 58 DASISION 58 romiplostim 58 TEMODAL 58 dasatinib 58 MYLOTARG 58 subcutaneous formulation 58 Proxinium TM 58 sNDA 58 metastatic renal cell carcinoma 58 randomized Phase 58 oral FTY# 58 NEBIDO 58 Zenvia ™ 58 forodesine 58 Troxatyl 58 Mepact 58 PDX pralatrexate 58 LEP ETU 58 Entereg R 58 rALLy trial 58 teduglutide 58 Pirfenidone 58 APPRAISE 58 sunitinib malate 58 elacytarabine 58 Anthim 58 PROSTVAC TM 58 advanced unresectable 58 MGCD# [001] 58 PhosLo 58 brivaracetam 58 Xcytrin 58 dacetuzumab 58 pomalidomide 58 FIRMAGON R 58 MabCampath 58 Octreolin 58 tezampanel 58 sorafenib 58 Folotyn 58 lesinurad 58 romidepsin 58 IRX 2 58 Romiplostim 58 Nabi HB Intravenous 58 Linjeta TM 58 EOquin TM 58 ATPace TM 58 Ixempra 58 Telavancin 58 PIX# [002] 58 severe hypercholesterolemia 58 otelixizumab 58 pixantrone 58 XGEVA 58 sNDA submission 58 Nexavar sorafenib 58 satraplatin Phase 58 RG# [001] 58 AzaSite Plus 58 HspE7 58 investigational monoclonal antibody 58 ONGLYZA 58 BYDUREON 58 Alzhemed TM 58 recurrent GBM 58 erlotinib Tarceva ® 58 ENTEREG ® 58 hormone refractory prostate cancer 58 Tovaxin 58 Phase IIb clinical 58 telaprevir VX 58 BENLYSTA ® 58 FUSILEV 58 IND submission 58 CIMZIA ™ 57 afatinib 57 galiximab 57 fidaxomicin 57 PROPEL trial 57 Valortim 57 THALOMID 57 Phase Ib 57 tesmilifene 57 LEUKINE 57 TOLAMBA 57 anti EGFR antibody 57 NEUPOGEN 57 Certican 57 lintuzumab SGN 57 OHR/AVR# 57 Cimzia TM 57 CTAP# Capsules 57 Ophena TM 57 Gemzar ® 57 ATryn R 57 eculizumab 57 nitazoxanide 57 Navelbine ® 57 Plicera 57 FOLFIRI 57 Marketing Authorization Application MAA 57 dacarbazine 57 cetuximab Erbitux 57 ambrisentan 57 virus HCV protease inhibitor 57 TroVax ® 57 pegloticase 57 Biologic License Application BLA 57 ORENCIA ® 57 UPLYSO 57 orBec ® 57 Exelbine 57 peginesatide 57 neratinib 57 Phase 2b clinical 57 thymalfasin 57 Targretin capsules 57 albinterferon alfa 2b 57 TAXOTERE R 57 Neuradiab 57 NDA submission 57 SUTENT 57 FOLFOX4 57 PANVAC VF 57 vosaroxin 57 AVADO 57 eribulin 57 Cloretazine 57 Marketing Authorisation Application 57 relapsed multiple myeloma 57 MyVax 57 zoledronic acid 57 Quinamed 57 Tarceva erlotinib 57 cutaneous T 57 daclizumab 57 MEK inhibitor RDEA# 57 TMC# [002] 57 dirucotide 57 Increlex R 57 Viramidine 57 faropenem 57 oral prodrug 57 Corlux 57 QNEXA 57 diabetic neuropathic pain 57 HuLuc# 57 Topical Interferon Alpha 2b 57 dose escalation 57 prostate cancer CRPC 57 voreloxin 57 APOPTONE 57 cediranib 57 docetaxel Taxotere R 57 randomized Phase 2b 57 depsipeptide 57 PI3K/Akt pathway inhibitor 57 ISTODAX 57 celgosivir 57 PEG PAL 57 Phase 2a trial 57 CRMD# 57 AZILECT ® 57 phase IIa clinical 57 ERBITUX 57 oblimersen 57 Clofarabine 57 XL# SAR# 57 Asentar 57 Raptiva ® 57 velaglucerase alfa 57 octreotide implant 57 Androxal 57 docetaxel Taxotere 57 Nexavar ® 57 Silenor NDA 57 bosutinib 57 SANVAR 57 ProSavin 57 naronapride 57 generation purine nucleoside 57 Genasense R 57 ZEVALIN 57 CLARITY study 57 Phenserine 57 XELOX 57 TRIOLEX 57 Hepatocellular Carcinoma HCC 57 Ventavis 57 Cleviprex TM clevidipine 57 telbivudine 57 rhThrombin 57 TTF Therapy 57 BrachySil 57 recurrent glioblastoma multiforme 57 Phase 2b study 57 Aplidin 57 HEPLISAV 57 RANK Ligand inhibitor 57 Northera 57 HuMax CD4 57 taliglucerase alfa 57 SUCCEED trial 57 Panitumumab 57 indolent NHL 57 Panzem 57 surrogate endpoint 57 ridaforolimus 57 refractory CLL 57 Phase Ib II 57 Phase III clinical 57 bifeprunox 57 Biological License Application 57 posaconazole 57 BEXXAR 57 PEG SN# 57 REVLIMID R 57 vidofludimus 57 Gleevec Glivec 57 dasatinib Sprycel ® 57 RSD# iv 57 R sorafenib tablets 57 Evoltra TM 57 peginterferon alfa 57 SPRYCEL ® 57 Androxal ® 56 balsalazide tablet 56 RSD# oral 56 FDA Complete Response 56 efficacy endpoints 56 interferon therapy 56 Phase IIb trials 56 GALNS 56 Bortezomib 56 Leukine 56 Cinryze 56 G#DT 56 MYDICAR ® 56 cancer neuroendocrine tumor 56 ARCOXIA 56 REOLYSIN ® 56 vernakalant hydrochloride 56 PRECISE trial 56 belinostat 56 lorcaserin NDA 56 RSD# 56 L DOS# 56 myelodysplastic syndromes MDS 56 Telintra 56 nab paclitaxel 56 bosentan 56 tecarfarin 56 orphan designation 56 DORIBAX 56 sNDA filing 56 VNP#M 56 recurrent NSCLC 56 metastatic colorectal cancer 56 Phase IIa trial 56 Rhucin R 56 omacetaxine 56 Intravenous CP 56 NGX# 56 lumiliximab 56 eniluracil 56 capecitabine Xeloda R 56 ONCONASE 56 Phase Ib study 56 eritoran 56 refractory metastatic colorectal cancer 56 Hycamtin 56 LymphoStat B belimumab 56 Firazyr 56 AMEVIVE 56 OMP designation 56 ApoB SNALP 56 AVASTIN 56 non squamous NSCLC 56 Riquent 56 FTY# 56 ACTEMRA TM 56 KYNAPID 56 assessing T DM1 56 autologous cellular immunotherapy 56 REMICADE ® 56 tramiprosate Alzhemed TM 56 Campath alemtuzumab 56 Taxotere chemotherapy 56 Vion Pharmaceuticals 56 AGILECT R 56 DR Cysteamine 56 COMFORT II 56 APTIVUS ritonavir 56 Diamyd ® 56 chemoradiation 56 ADVEXIN p# therapy 56 Nebido 56 Phase #b/#a clinical 56 ELND# 56 Satraplatin 56 Cimzia ® certolizumab pegol 56 azficel T 56 BCIRG 56 REVLIMID lenalidomide 56 pertuzumab 56 Zavesca R 56 Fast Track designation 56 ALIMTA 56 goserelin 56 RDEA# 56 LE SN# 56 PD LID 56 T DM1 56 DexaSite 56 comparator arm 56 R#/MEM # 56 huC# DM4 56 trastuzumab DM1 56 PrevOnco ™ 56 bevacizumab Avastin 56 efficacy tolerability 56 Peginterferon alfa 2b 56 pegylated interferon alpha 56 Clevudine 56 vernakalant iv 56 PIX# trial 56 sorafenib Nexavar 56 oxypurinol 56 Reolysin 56 ferumoxytol 56 pain palliation 56 ZADAXIN ® 56 Glufosfamide 56 Xanafide 56 deforolimus 56 mcg dose 56 RAPTIVA 56 rNAPc2 56 Sym# 56 bortezomib Velcade 56 cystinosis patients 56 Rhucin 56 metastatic CRC 56 VPRIV 56 NATRECOR R 56 Genz # 56 investigational antiplatelet agent 56 Pivotal Phase 56 BiovaxID TM 56 Protexia R 56 REVLIMID 56 zalutumumab 56 SEBIVO 56 Taxotere R 56 obatoclax 56 Prostate AdenoCarcinoma Treatment 56 CCX# 56 investigational humanized monoclonal antibody 56 herpetic keratitis 56 antibody MAb 56 NEO3 56 sustained virologic response 56 zanolimumab 56 biologic therapy 56 sunitinib Sutent 56 KRAS status 56 refractory multiple myeloma 56 Q#IR 56 CUBICIN 56 pafuramidine 56 OvaRex R 56 Tarceva 56 LEVADEX 56 MERLIN TIMI 56 crizotinib PF # 56 LibiGel ® 56 DAVANAT R 56 oritavancin 56 alogliptin 56 XYOTAX 56 ANTEGREN 56 vernakalant oral 56 Rebif ® 56 Mylotarg 56 hereditary deficiency 56 HuMax EGFr 56 EGFR expressing metastatic colorectal 56 acyclovir Lauriad R 56 mCRC 56 castrate resistant prostate cancer 56 ularitide 56 BLP# Liposome Vaccine 56 randomized Phase III 56 Junovan TM 56 PrevOnco 56 Exherin TM 56 oral deforolimus 56 paclitaxel Taxol ® 56 Generx 56 Xinlay 56 Increlex ® 56 Phase 2b trial 56 HGS# 56 lurasidone 56 ASONEP 56 velafermin belinostat 56 Vilazodone 56 investigational therapies 56 Fampridine SR 56 pharmacokinetic studies 56 lapatinib Tykerb 56 MGd 56 YERVOY 56 Removab 56 chlorambucil 56 Mozobil 56 PEGINTRON 56 Advagraf 56 adalimumab Humira 56 Gencaro 56 Azilect ® 56 Cimzia 56 Zalbin 56 gefitinib 56 Acetavance 56 carfilzomib 56 application sNDA 56 Halaven 55 Rasilez Tekturna 55 bendamustine 55 DPX Survivac 55 Nexavar 55 FIRAZYR 55 PS# [001] 55 Cloretazine R 55 eprotirome 55 nalbuphine ER 55 FACTIVE tablets 55 cangrelor 55 CANCIDAS 55 sodium Injection 55 Doxil ® 55 satraplatin 55 Fast Track designations 55 Hedgehog Pathway Inhibitor 55 Cellegesic 55 NovoTTF 55 viral kinetics 55 optimal dosing 55 nilotinib 55 Abiraterone acetate 55 ADVEXIN clinical 55 Treanda 55 TLK# 55 SILENOR 55 arimoclomol 55 thetreatment 55 Renvela 55 Zelrix 55 unresectable 55 Locteron 55 Exelbine NDA 55 Alocrest 55 Xelox 55 Surfaxin LS 55 TACI Ig 55 placebo controlled Phase 55 Abraxane 55 Stimuvax 55 dosing cohort 55 remission induction 55 Phase IIb 55 Orphan Drug status 55 PRECISE Trial 55 dalbavancin 55 MAXY alpha 55 cSSSI 55 ImClone Erbitux 55 Vasovist 55 pseudobulbar affect PBA 55 phase III isavuconazole 55 bortezomib 55 eprodisate KIACTA TM 55 tolevamer 55 docetaxel 55 Pralatrexate 55 Plenaxis R 55 icatibant 55 histone deacetylase HDAC inhibitor 55 telaprevir 55 CIMZIA TM certolizumab pegol 55 phase IIb study 55 hepatocellular cancer 55 EDEMA4 55 paclitaxel Taxol R 55 castration resistant prostate cancer 55 standard chemotherapy regimens 55 CYT# 55 radiation sensitizer 55 ILLUMINATE 55 plus prednisone 55 RoACTEMRA 55 trastuzumab Herceptin R 55 ONCASPAR 55 Cimzia R 55 ARIKACE 55 Roche Actemra 55 lomitapide 55 NPSP# 55 VELCADE melphalan 55 gefitinib Iressa 55 Zenvia 55 alfa 2a 55 tipranavir 55 docetaxel Taxotere ® 55 riociguat 55 rindopepimut 55 IPLEX 55 anticancer compound 55 AEG# 55 entinostat 55 MEND CABG II 55 IV acetaminophen 55 Novartis Zometa 55 REBETOL combination therapy 55 GVAX 55 Pemetrexed 55 ThermoDox 55 Virulizin ® 55 MGN# 55 NEUVENGE 55 dexanabinol 55 REVLIMID ® 55 Triapine R 55 vemurafenib 55 advanced NSCLC 55 interferon alfa 55 stage IIIB 55 vinflunine 55 histamine dihydrochloride 55 oral methylnaltrexone 55 tremelimumab 55 bicifadine 55 oncology indications 55 CLIRS trial 55 lenalidomide Revlimid R 55 Centralized Procedure 55 Personalized Immunotherapy 55 Phase IIIb clinical 55 metastatic GIST 55 PRT# 55 methylnaltrexone 55 teriflunomide 55 TRISENOX ® 55 mertansine 55 APTIVUS 55 refractory gout 55 KNS # 55 cetuximab Erbitux R 55 ADAGIO study 55 Egrifta 55 Dr. McHutchison 55 randomized multicenter Phase III 55 dextromethorphan quinidine 55 DAVANAT 55 paliperidone ER 55 cabazitaxel 55 Fx #A 55 efalizumab 55 Afinitor 55 pivotal Phase 55 VEGF Trap 55 ORENCIA R 55 opioid induced bowel dysfunction 55 ThermoDox ® 55 clinical endpoints 55 FDA Oncologic Drugs 55 HyQ 55 EndoTAGTM 1 55 metastatic HRPC 55 Diabetic Macular Edema 55 Evoltra ® 55 ACZ# 55 Poly ICR 55 SILENOR ™ 55 natalizumab 55 ARIXTRA 55 IMGN# 55 Chemophase 55 Trofex 55 Pivotal Phase III 55 HCD# [002] 55 Soliris eculizumab 55 Sandostatin LAR 55 Allovectin 7 r 55 leading oral taxane 55 trastuzumab 55 Perifosine 55 MabThera Rituxan 55 Iluvien 55 BEMA TM LA 55 Itopride 55 recurrent metastatic 55 plus gemcitabine 55 Dalbavancin 55 Copegus ribavirin 55 Onco TCS 55 systemically administered 55 urocortin 2 55 confirmatory clinical 55 AeroLEF TM 55 MoxDuo IR 55 EGFR TKI 55 Solazed 55 GTC recombinant human 55 GRN#L 55 brentuximab vedotin SGN 55 COPEGUS 55 hematological cancers 55 Zybrestat 55 Romidepsin 55 MyVax personalized immunotherapy 55 Aflibercept 55 Cinryze ™ 55 oxaliplatin Eloxatin 55 Ganite R 55 gemcitabine 55 UVIDEM 55 Onbrez Breezhaler 55 supplemental Biologics License Application 55 ATryn ® 55 B CLL 55 stage IIIB IV 55 ZACTIMA 55 ALN VSP 55 Lenalidomide 55 hypercalcemia 55 cetuximab Erbitux ® 55 clodronate 54 gastrointestinal stromal tumors 54 Raptiva R 54 Dendreon Provenge 54 mitogen activated ERK kinase 54 CA4P 54 fluoropyrimidine 54 myelodysplastic syndromes 54 dose cohorts 54 Entereg TM 54 Advexin 54 Neulasta ® 54 DCVax R Brain 54 Phase IIB 54 cytotoxic chemotherapy 54 visilizumab 54 Veronate 54 successfully commercialize Iluvien 54 Zenvia TM 54 achieve sustained virologic 54 CDP# 54 HERmark 54 Vectibix panitumumab 54 BiTE antibody 54 Pruvel 54 Fodosine 54 Anturol TM 54 forodesine hydrochloride 54 NP2 Enkephalin 54 ELADUR 54 apremilast 54 Neuvenge 54 Triolex 54 FDA approvable letter 54 CHMP recommendation 54 rasagiline tablets 54 DAVANAT ® 54 HoFH 54 COPAXONE ® 54 sorafenib Nexavar ® 54 opioid induced constipation 54 SAR# [004] 54 Ocrelizumab 54 SABCS 54 pitavastatin 54 PEG interferon 54 PSN# [002] 54 MAXY G# 54 abatacept 54 orphan medicinal product 54 voclosporin 54 ribavirin RBV 54 favorable pharmacokinetic profile 54 VFEND 54 Cimzia ® 54 Aclasta 54 ANA# 54 peg IFN 54 tramiprosate ALZHEMED TM 54 Ixabepilone 54 TBC# 54 Bicifadine 54 PLX PAD 54 Phase 1a clinical 54 LUX Lung 54 pralatrexate injection 54 Actimmune ® 54 Golimumab 54 motesanib 54 personalized immunotherapy 54 VALSTAR 54 Androxal TM 54 ADVENTRX 54 maximally tolerated dose 54 evaluating picoplatin 54 ZEGERID Capsules 54 cUTI 54 KRN# 54 RhuDex ® 54 AQ4N 54 Elagolix 54 Aptivus ® 54 pradefovir 54 free survival PFS 54 Relivar 54 RAV# 54 Tectin TM 54 INTERCEPT platelets 54 advanced carcinoid 54 evaluating REVLIMID 54 recurrent GBM patients